VELTIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VELTIN (VELTIN).
Fixed-dose combination of clindamycin (a lincosamide antibiotic) and tretinoin (a retinoid). Clindamycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Tretinoin reduces microcomedone formation by normalizing follicular keratinization.
| Metabolism | Clindamycin: Hepatic metabolism primarily via CYP3A4, with some metabolites active. Tretinoin: Oxidative metabolism via CYP450 enzymes, with further conjugation and excretion. |
| Excretion | Renal (primarily unchanged drug, ~60% within 96 hours); fecal (~35%, with ~9% as metabolites). |
| Half-life | Terminal elimination half-life is approximately 17 hours (range 10-24 h) after oral administration. This supports twice-daily dosing in adults. |
| Protein binding | Clindamycin is 60-95% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | Vd is approximately 0.6 L/kg (43 L in a 70 kg adult), indicating distribution into total body water. |
| Bioavailability | Oral: ~90% absorbed; however, systemic bioavailability is reduced by extensive first-pass metabolism (to active and inactive metabolites). |
| Onset of Action | Oral: Clinical effect (improvement in acne lesions) typically observed within 2-4 weeks of continuous therapy. |
| Duration of Action | Duration of action is approximately 24 hours, consistent with twice-daily dosing. Maximal therapeutic benefit may require 8-12 weeks of treatment. |
Apply a thin layer to affected area once daily in the evening; topical, not for oral or ophthalmic use.
| Dosage form | GEL |
| Renal impairment | No dosage adjustment required for renal impairment; not studied in severe renal impairment. |
| Liver impairment | No specific dosage adjustment provided; caution in severe hepatic impairment due to potential increased systemic absorption. |
| Pediatric use | Safety and efficacy in pediatric patients below 9 years of age have not been established; for ages 9 and above, same as adult dosing. |
| Geriatric use | No specific geriatric dosage adjustments; use caution due to potential increased sensitivity and age-related skin changes. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VELTIN (VELTIN).
| Breastfeeding | Unknown if clindamycin or tretinoin excreted into human milk following topical application. Clindamycin can be absorbed systemically and may appear in milk; potential for adverse effects (diarrhea, candidiasis) in nursing infant. M/P ratio: not established. Use with caution; alternative therapy recommended. |
| Teratogenic Risk | VELTIN contains clindamycin phosphate 1.2% and tretinoin 0.025%. Tretinoin is a retinoid; topical use is associated with minimal systemic absorption. However, retinoids are known teratogens when absorbed systemically. First trimester: theoretical risk of retinoid embryopathy (CNS, cardiovascular, craniofacial defects). Second/third trimester: risk likely low but avoid unless necessity. No adequate human studies. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to any component","History of regional enteritis, ulcerative colitis, or antibiotic-associated colitis"]
| Precautions | ["Avoid contact with eyes, mouth, and mucous membranes.","Photosensitivity: Minimize sun exposure and use sunscreen.","Local skin reactions (erythema, peeling, dryness, pruritus) may occur.","Colitis (including pseudomembranous colitis) has been reported with topical clindamycin."] |
Loading safety data…
| Fetal Monitoring | Monitor for signs of excessive skin irritation or retinoid toxicity. Fetal monitoring: standard prenatal care; discuss potential theoretical risks with patient. No specific fetal tests required. |
| Fertility Effects | No known effects on fertility. Topical tretinoin and clindamycin have minimal systemic absorption; no impairment of reproductive function reported. |